

X I . News Releases

Major news releases during April 2009 - September 2009 are as below.

Please refer to our web site for details (<http://www.takeda.com/>).

Date	Summary
9-Apr-09	Nature Publishes Pre-clinical Data on an Inhibitor of a Novel Target Discovered by Millennium
23-Apr-09	Lancet Publishes Phase 3 Clinical Data on Basen®
7-May-09	Takeda to integrate its two manufacturing operations in Ireland
7-May-09	Takeda to Start Sales and Marketing Operation in Portugal
14-May-09	FDA Approves ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes First and only oral antidiabetic fixed-dose combination medication approved with the extended-release form of metformin
18-May-09	Takeda to Acquire IDM Pharma, Adding Mepact (Mifamurtide), The First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
26-May-09	Takeda to License Vaccine for Haemophilus Influenzae Type B from Novartis
4-Jun-09	Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filing in Europe
8-Jun-09	Update on Lu AA21004 clinical development programme in major depressive disorder (MDD)
18-Jun-09	New Dosage Combination of Blopress® and diuretic Launched in First European Market
23-Jun-09	Takeda's Investigational Compound TAK-536 for Treatment of Hypertension Enters into Phase 3 Clinical Trials in Japan
23-Jun-09	Takeda Establishes "Takeda Global Advisory Board"
27-Jun-09	Takeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes
29-Jun-09	Takeda Submitted an Application for an Additional Indication of Alogliptin for Combination Therapy with Thiazolidinediones, and a New Drug Application of Fixed-Dose Combination of Alogliptin and Pioglitazone HCl in Japan
7-Jul-09	CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer
8-Jul-09	ENBREL to Add Indication of Juvenile Idiopathic Arthritis (JIA)
23-Jul-09	Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl)
27-Jul-09	Agreements Concluded for "SELTOUCH ® Pap 70, 140" Transdermal Absorption-type Analgesic and Anti-inflammatory Agent
27-Jul-09	Takeda Submits a New Drug Application for a Fixed-Dose Combination Tablet of Actos ® with sulfonylurea in Japan
28-Aug-09	Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
3-Sep-09	Initiation of Pivotal Phase III Study with Catena®/Sovrima® (Idebenone) in Duchenne Muscular Dystrophy
3-Sep-09	Terumo and Takeda to Co-promote Takeda's Ethical Narcotic Formulations
4-Sep-09	Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS® (pioglitazone HCl) for the Treatment of Type 2 Diabetes
11-Sep-09	Millennium Initiates Phase II Trial of Prostate Cancer Compound